Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mindy A Bowers"'
Autor:
Patricia A. Ganz, Ting Wang, Jihye Yoon, Oliver W. Press, Richard I. Fisher, Mindy A Bowers, Gretchen S. Gatti, Harry P. Erba, Mark S. Kaminski, Alice B. Kornblith, Ellen R. Gaynor, Joseph M. Unger, Carol M. Moinpour
Publikováno v:
Journal of Cancer Survivorship. 11:32-40
We describe 7 years of follow-up for the energy/vitality outcome in early-stage Hodgkin’s disease patients treated on a randomized clinical trial that compared subtotal lymphoid irradiation (STLI) with combined modality treatment (CMT) (SWOG 9133).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abae99b3b9452f8130d429fa1f8b7cda
https://doi.org/10.1007/s11764-016-0559-y
https://doi.org/10.1007/s11764-016-0559-y
Autor:
Yvonne A. Efebera, Nita Williams, Don M. Benson, Kristina Humphries, Ying Huang, Craig C. Hofmeister, Steven M. Devine, Douglas W. Sborov, Mindy A Bowers
Publikováno v:
British Journal of Haematology. 171:74-83
Single-agent post-autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma. The tolerability and effectiveness of combination post-transplant maintenance therapy is unknown, so we investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8cc9af940531b7592856e122ea28e9
https://doi.org/10.1111/bjh.13527
https://doi.org/10.1111/bjh.13527
Autor:
Anissa Bingman, Joseph M. Flynn, John A. Vaughn, Nita Williams, Gerard Lozanski, Sam Penza, Mindy A Bowers, Susan Geyer, Robert A. Baiocchi, Pierluigi Porcu, Samantha Jaglowski, Don M. Benson, Erinn M. Hade, Christian T. Earl, Craig C. Hofmeister, Kristina Humphries, Steven M. Devine, Kristie A. Blum, Leslie A. Andritsos
Publikováno v:
Leukemia & Lymphoma. 56:1043-1049
Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63c4f9f160482e47fcb056fb9c1eb64
https://doi.org/10.3109/10428194.2014.963073
https://doi.org/10.3109/10428194.2014.963073
Autor:
Sherif S. Farag, Eric H. Kraut, Jennifer Sexton, Mindy A Bowers, Craig C. Hofmeister, Ming Poi, Michael R. Grever, John C. Byrd, Thomas S. Lin, Mitch A. Phelps, Weiqiang Zhao, Don M. Benson, Yvonne A. Efebera
Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile.Patients with a diagnosis of relapsed myeloma aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7460a486c8a96ad80d75d757148331b3
https://europepmc.org/articles/PMC3946636/
https://europepmc.org/articles/PMC3946636/
Autor:
Yvonne A. Efebera, Carli N Greenfield, Mindy A Bowers, Kristina Humphries, Anissa Bingman, William Falk, Mark E. Lustberg, Christian T. Earl, Susan Geyer, Craig C. Hofmeister, Steven M. Devine, Gerard Lozanski, Megan Sell, John L Vaughn, Robert A. Baiocchi, Don M. Benson
Publikováno v:
Blood. 120:4460-4460
Abstract 4460 Introduction: Multiple myeloma patients after autologous hematopoietic stem cell transplant (HSCT) achieve a minimal residual disease state, providing an opportunity for immunomodulatory therapy – but the details of immune recovery af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cef41b9c366f468ff8327a62bc92ff4
https://doi.org/10.1182/blood.v120.21.4460.4460
https://doi.org/10.1182/blood.v120.21.4460.4460
Autor:
Carli N Greenfield, Zhongfa Liu, Megan Sell, Mindy A Bowers, Susan Geyer, Leslie A. Andritsos, Don M. Benson, John C. Byrd, Beth Christian, Pierluigi Porcu, Craig C. Hofmeister, Robert A. Baiocchi, Joseph M. Flynn, Michael R. Grever
Publikováno v:
Blood. 120:2955-2955
Abstract 2955 Introduction: Deacetylase (DAC) inhibitors show promise as anti-neoplastic agents, the approved drugs are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have suboptimal activity or unacceptable toxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1f1bc47a09108e9e1c3ea9779fbe936
https://doi.org/10.1182/blood.v120.21.2955.2955
https://doi.org/10.1182/blood.v120.21.2955.2955
Autor:
Carli N Greenfield, Megan Sell, Kristina Humphries, Don M. Benson, Yvonne A. Efebera, Mindy A Bowers, Steven M. Devine, Craig C. Hofmeister
Publikováno v:
Blood. 120:3114-3114
Abstract 3114 Introduction: Post autologous transplant maintenance therapy for patients with multiple myeloma (MM) is standard of care (McCarthy et al, NEJM, 2012). Vorinostat (SAHA, Zolinza) is a HDAC inhibitor for which preclinical evidence suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cbf1478b1f6d0041f54bd1245d3f1a1
https://doi.org/10.1182/blood.v120.21.3114.3114
https://doi.org/10.1182/blood.v120.21.3114.3114
Autor:
Christian T. Earl, Craig C. Hofmeister, Kristina Humphries, Steven M. Devine, Pierluigi Porcu, Leslie A. Andritsos, Carl Quinion, Kristie A. Blum, Joseph Zitesman, Sam Penza, Gerard Lozanski, Carli N Greenfield, Megan Sell, Mindy A Bowers, Mark E. Lustberg, Robert A. Baiocchi
Publikováno v:
Blood. 120:2004-2004
2004 [][1] Introduction: Autologous hematopoietic stem cell transplantation (HSCT) cures fewer than half of patients with aggressive non-Hodgkin's lymphoma (NHL). Vorinostat (SAHA, Zolinza) has shown activity in relapsed lymphoma and there is preclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ed9e59d940ced9059acb175540ba8ea
https://doi.org/10.1182/blood.v120.21.2004.2004
https://doi.org/10.1182/blood.v120.21.2004.2004
Autor:
Todd M. Zimmerman, Sandra Wear, Ravi Vij, Rachel Hagerty, Mark A. Fiala, Engin Gul, Amrita Krishnan, Robert F Ott, Noopur Raje, Donna E. Reece, Mindy A Bowers, Michele Maharaj, Ann Birgin, Vivek Roy, Leah Tasca, Sundar Jagannath, David S. Siegel, Shaji Kumar, Alaina R. Mitchell, Paul G. Richardson, Adolfo Aleman, Daniel Larsen, Kathy Giusti, Sagar Lonial, Jeffrey L. Wolf, Lupe Duarte, Lisa La, A. Keith Stewart, Joseph W. Fay, Carolyn Revta, Diane E. Durecki, Kenneth C. Anderson, Craig C. Hofmeister, Tracey Messing, Geraldine Pelle-Day, Andrzej Jakubowiak, Ajai Chari
Publikováno v:
Blood. 118:1024-1024
Abstract 1024 Background: The MMRC is a non-profit, disease-focused consortium founded in 2004. Sixteen North American member institutions with expertise in multiple myeloma (MM) work collaboratively with the MMRC Inc. (Norwalk, CT) and numerous phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e6697bbed70f74939a30f0c48075260
https://doi.org/10.1182/blood.v118.21.1024.1024
https://doi.org/10.1182/blood.v118.21.1024.1024
Autor:
Lisa C Merritt, Don M. Benson, Mindy A Bowers, Janet S. de Moor, Gisele Rieser, Steven M. Devine, Craig C. Hofmeister, Carli N Greenfield, Yvonne A. Efebera
Publikováno v:
Blood. 116:3807-3807
Abstract 3807 Intro: Multiple myeloma (MM) is an incurable clonal plasma cell cancer characterized by a microenvironment of inflammatory cytokines, specifically IL-6, VEGF, TNF-α, and marrow stromal cells that all support the growth of myeloma cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e27c2751a4aedd4dc365f7239150bf77
https://doi.org/10.1182/blood.v116.21.3807.3807
https://doi.org/10.1182/blood.v116.21.3807.3807